Dumnoensun Pruksakorn

Dr. Dumnoensun Pruksakorn


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SOSanthasiri Orrapin
Santhasiri Orrapin
SUSasimol Udomruk
Sasimol Udomruk
WLWorakitti Lapisatepun
Worakitti Lapisatepun
SMsutpirat moonmuang
sutpirat moonmuang
APAreerak Phanphaisarn
Areerak Phanphaisarn
PCParunya Chaiyawat
Parunya Chaiyawat
Circulating tumor cells (CTCs) play a key role in hematogenous metastasis and post-surgery recurrence. In hepatocellular carcinoma (HCC), CTCs have emerged as a valuable source of therapeutically relevant information. Certain subsets or phenotypes of CTCs can survive in the bloodstream and induce metastasis. Here, we performed a systematic review on the importance of epithelial–mesenchymal transition (EMT)-CTCs and circulating cancer stem cells (CCSCs) in metastatic processes and their prognostic power in HCC management. PubMed, Scopus, and Embase databases were searched for relevant publications. PRISMA criteria were used to review all studies. Twenty publications were eligible, of which 14, 5, and 1 study reported EMT-CTCs, CCSCs, and both phenotypes, respectively. Most studies evaluated that mesenchymal CTCs and CCSCs positivity were statistically associated with extensive clinicopathological features, including larger size and multiple numbers of tumors, advanced stages, micro/macrovascular invasion, and metastatic/recurrent disease. A preliminary meta-analysis showed that the presence of mesenchymal CTCs in pre- and postoperative blood significantly increased the risk of early recurrence. Mesenchymal-CTCs positivity was the most reported association with inferior outcomes based on the prognosis of HCC recurrence. Our finding could be a step forward, conveying additional prognostic values of CTC subtypes as promising biomarkers in HCC management.

1 October 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
SUSasimol Udomruk
Sasimol Udomruk
SOSanthasiri Orrapin
Santhasiri Orrapin
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn
PCParunya Chaiyawat
Parunya Chaiyawat

3 August 2020 in Materials
Verified
Journal Article
Open access
PDF file
KTKittiya Thunsiri
Kittiya Thunsiri
SPSiwasit Pitjamit
Siwasit Pitjamit
PPPeraphan Pothacharoen
Peraphan Pothacharoen
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn
WNWasawat Nakkiew
Wasawat Nakkiew
Wassanai WattanutchariyaWassanai Wattanutchariya
Wassanai Wattanutchariya
The full-thickness articular cartilage defect (FTAC) is an abnormally severe grade of articular cartilage (AC) injury. An osteochondral autograft transfer (OAT) is the recommended treatment, but the increasing morbidity rate from osteochondral plug harvesting is a limitation. Thus, the 3D-printed bilayer’s bioactive-biomaterials scaffold is of major interest. Polylactic acid (PLA) and polycaprolactone (PCL) were blended with hydroxyapatite (HA) for the 3D-printed bone layer of the bilayer’s bioactive-biomaterials scaffold (B-BBBS). Meanwhile, the blended PLA/PCL filament was 3D printed and combined with a chitosan (CS)/silk firoin (SF) using a lyophilization technique to fabricate the AC layer of the bilayer’s bioactive-biomaterials scaffold (AC-BBBS). Material characterization and mechanical and biological tests were performed. The fabrication process consists of combining the 3D-printed structure (AC-BBBS and B-BBBS) and a lyophilized porous AC-BBBS. The morphology and printing abilities were investigated, and biological tests were performed. Finite element analysis (FEA) was performed to predict the maximum load that the bilayer’s bioactive-biomaterials scaffold (BBBS) could carry. The presence of HA and CS/SF in the PLA/PCL structure increased cell proliferation. The FEA predicted the load carrying capacity to be up to 663.2 N. All tests indicated that it is possible for BBBS to be used in tissue engineering for AC and bone regeneration in FTAC treatment.

14 October 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JKJeerawan Klangjorhor
Jeerawan Klangjorhor
PCParunya Chaiyawat
Parunya Chaiyawat
PTPimpisa Teeyakasem
Pimpisa Teeyakasem
NSNutnicha Sirikaew
Nutnicha Sirikaew
APAreerak Phanphaisarn
Areerak Phanphaisarn
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn

4 July 2016 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
DPDumnoensun Pruksakorn
Dumnoensun Pruksakorn
PTPimpisa Teeyakasem
Pimpisa Teeyakasem
JKJeerawan Klangjorhor
Jeerawan Klangjorhor
PCParunya Chaiyawat
Parunya Chaiyawat
JSJongkolnee Settakorn
Jongkolnee Settakorn
CSChantragan Srisomsap
Chantragan Srisomsap
Osteosarcoma is a common malignant bone tumor in children and adolescents. The current 5-year survival rate is ~60% and that seems to be reaching a plateau. In order to improve treatment outcomes of osteosarcoma, a better understanding of tumorigenesis and underlying molecular mechanisms is required for searching out possible new treatment targets. This study aimed to identify the potential proteins involving the pathogenesis of osteosarcoma using a proteomics approach. Proteins extracted from primary cell culture of osteosarcoma (n=7) and osteoblasts of cancellous bone (n=7) were studied. Using 2-DE based proteomics and LC-MS/MS analysis, we successfully determined seven differentially expressed protein spots. Four upregulated proteins and three downregulated proteins were observed in this study in which KH-type splicing regulatory protein (KSRP) was selected for further exploration. KSRP was significantly upregulated in osteosarcoma cells compared to osteoblasts using western blot assay. In addition, immunohistochemistry demonstrated that KSRP was also highly expressed in osteosarcoma tissue of independent cases from the experimental group. More importantly, KSRP silencing of osteosarcoma cell lines significantly decreased cell proliferation, migration ability, as well as implantation and growth ability in chick chorioallantoic membrane assay. Taken together, these findings demonstrate, that KSRP plays important roles in regulatory controls of osteosarcoma pathogenesis and serves as a potentially therapeutic target of osteosarcoma.

Verified
Journal Article
Open access
PDF file
SOSanthasiri Orrapin
Santhasiri Orrapin
PTPatcharawadee Thongkumkoon
Patcharawadee Thongkumkoon
SUSasimol Udomruk
Sasimol Udomruk
SMsutpirat moonmuang
sutpirat moonmuang
SSSongphon Sutthitthasakul
Songphon Sutthitthasakul
PCParunya Chaiyawat
Parunya Chaiyawat
Circulating tumor cells (CTCs) hold unique biological characteristics that directly involve them in hematogenous dissemination. Studying CTCs systematically is technically challenging due to their extreme rarity and heterogeneity and the lack of specific markers to specify metastasis-initiating CTCs. With cutting-edge technology, single-cell RNA sequencing (scRNA-seq) provides insights into the biology of metastatic processes driven by CTCs. Transcriptomics analysis of single CTCs can decipher tumor heterogeneity and phenotypic plasticity for exploring promising novel therapeutic targets. The integrated approach provides a perspective on the mechanisms underlying tumor development and interrogates CTCs interactions with other blood cell types, particularly those of the immune system. This review aims to comprehensively describe the current study on CTC transcriptomic analysis through scRNA-seq technology. We emphasize the workflow for scRNA-seq analysis of CTCs, including enrichment, single cell isolation, and bioinformatic tools applied for this purpose. Furthermore, we elucidated the translational knowledge from the transcriptomic profile of individual CTCs and the biology of cancer metastasis for developing effective therapeutics through targeting key pathways in CTCs.